SEARCH:   Advanced

Blood, 1 April 2007, Vol. 109, No. 7, pp. 2759-2766. Prepublished online as a Blood First Edition Paper on November 28, 2006; DOI 10.1182/blood-2006-07-035709. This Article Full Text (PDF) Supplemental Appendix All Versions of this Article: blood-2006-07-035709v1 109/7/2759    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Verdonck, L. F Articles by van Imhoff, G. W Search for Related Content PubMed PubMed Citation Articles by Verdonck, L. F Articles by van Imhoff, G. W Social Bookmarking                   What's this?  Previous Article  |  Next Article  Submitted July 14, 2006 Accepted November 17, 2006 Intensified CHOP of 12-weeks duration (I-CHOP) plus G-CSF compared with standard CHOP of 24-weeks duration (CHOP-21) for patients with intermediate-risk aggressive non-Hodgkin's Lymphoma. A phase III trial of the Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON) Leo F Verdonck*, Annelise Notenboom, Daphne D de Jong, Marius A MacKenzie, Gregor E.G. Verhoef, Mark H.H. Kramer, Gert J Ossenkoppele, Jeanette K Doorduijn, Pieter Sonneveld, and Gustaaf W van Imhoff University Medical Center, Netherlands HOVON Data Center, Erasmus Medical Center, Netherlands Netherlands Cancer Institute, Netherlands University Hospital Gasthuisberg, Belgium Meander Medical Center, Netherlands VU Medical Center, Netherlands Erasmus Medical Center, Netherlands * Corresponding author; email: l.f.verdonck{at}umcutrecht.nl. Optimal dose and timing of CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) chemotherapy for aggressive non-Hodgkin's lymphoma (NHL) is still an unresolved issue. We assessed whether dose intensifications with cyclophosphamide and doxorubicin might improve outcome in younger patients with intermediate-risk aggressive NHL. Previously untreated patients were assigned to receive either 8 courses of standard CHOP (n=239) or 6 courses of intensified (I)-CHOP (n= 238). Although there was a tendency in favour of I-CHOP for overall survival (OS), disease-free survival (DFS), and event-free survival (EFS), the differences were not significant .However, although these analyses were not planned, when the intermediate-risk group was divided into low-intermediate and high-intermediate risk patients according to the International Prognostic Index (IPI), low-intermediate risk patients had improved 6 year OS (67% versus 52% ; p=0.05), DFS (58% versus 45% ; p=0.06), and EFS ( 41 % versus 30%; p=0.21) when they were treated with I-CHOP compared with standard CHOP. On the other hand, high-intermediate risk patients seem to have no benefit of I-CHOP. Although clinically relevant side-effects occurred more often in the I-CHOP arm, treatment-related mortality was similar. These data suggest that I-CHOP might be preferable to standard CHOP in younger patients with low-intermediate risk aggressive NHL. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: E. Derenzini, M. P. Fina, V. Stefoni, C. Pellegrini, F. Venturini, A. Broccoli, L. Gandolfi, S. Pileri, S. Fanti, E. Lopci, et al. MACOP-B regimen in the treatment of adult Langerhans cell histiocytosis: experience on seven patients Ann. Onc., October 27, 2009; (2009) mdp455v1. [Abstract] [Full Text] [PDF] H.A. Azim, L. Santoro, R.G. Bociek, S. Gandini, R.A. Malek, and H.A. Azim Jr High dose intensity doxorubicin in aggressive non-Hodgkin's lymphoma: a literature-based meta-analysis Ann. Onc., October 22, 2009; (2009) mdp425v1. [Abstract] [Full Text] [PDF] W. H. Wilson, K. Dunleavy, S. Pittaluga, U. Hegde, N. Grant, S. M. Steinberg, M. Raffeld, M. Gutierrez, B. A. Chabner, L. Staudt, et al. Phase II Study of Dose-Adjusted EPOCH and Rituximab in Untreated Diffuse Large B-Cell Lymphoma With Analysis of Germinal Center and Post-Germinal Center Biomarkers J. Clin. Oncol., June 1, 2008; 26(16): 2717 - 2724. [Abstract] [Full Text] [PDF] G. P. Canellos What Constitutes "Improved Prognosis"? J. Clin. Oncol., April 20, 2008; 26(12): 1913 - 1914. [Full Text] [PDF] P. Morel, P. Gaulard, C. Gisselbrecht, C. Ferme, G. Salles, H. Tilly, J. Briere, M. C. Copin, P. Lederlin, O. Hermine, et al. Autologous stem-cell transplantation as consolidation therapy for diffuse large B-cell lymphoma patients with overexpression of bcl-2 protein. Results of the Groupe d'Etude des Lymphomes de l'Adulte (GELA) trial LNH98-B2 Ann. Onc., March 1, 2008; 19(3): 560 - 565. [Abstract] [Full Text] [PDF]

	Copyright © 2006 by American Society of Hematology         Online ISSN: 1528-0020